公开(公告)号：US20210246137A1

公开(公告)日：2021-08-12

申请号：US17237351

申请日：2021-04-22

申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services ,  Loyola University of Chicago

发明人： Wenwei Huang ,  Hao Li ,  Wei Sun ,  Xiuli Huang ,  Paresma R. Patel ,  Hangmao Sun ,  Wei Zheng ,  Xiao Lu ,  Philip E. Sanderson ,  Myunghoon Kim ,  Meghan J. Orr ,  Gregory J. Tawa ,  Kim C. Williamson

IPC分类号： C07D471/04 ,  A61P33/06 ,  C07D487/04 ,  C07D487/08 ,  C07D519/00

摘要： Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

公开(公告)号：US20190315740A1

公开(公告)日：2019-10-17

申请号：US16341000

申请日：2017-10-13

申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services ,  Loyola University of Chicago

发明人： Wenwei Huang ,  Hao Li ,  Wei Sun ,  Xiuli Huang ,  Paresma R. Patel ,  Hangmao Sun ,  Wei Zheng ,  Xiao Lu ,  Philip E. Sanderson ,  Myunghoon Kim ,  Meghan J. Orr ,  Gregory J. Tawa ,  Kim C. Williamson

IPC分类号： C07D471/04 ,  C07D487/04 ,  A61P33/06 ,  C07D487/08 ,  C07D519/00

摘要： Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

公开(公告)号：US10988472B2

公开(公告)日：2021-04-27

申请号：US16341000

申请日：2017-10-13

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services ,  Loyola University of Chicago

发明人： Wenwei Huang ,  Hao Li ,  Wei Sun ,  Xiuli Huang ,  Paresma R. Patel ,  Hangmao Sun ,  Wei Zheng ,  Xiao Lu ,  Philip E. Sanderson ,  Myunghoon Kim ,  Meghan J. Orr ,  Gregory J. Tawa ,  Kim C. Williamson

IPC分类号： C07D471/06 ,  A61K31/4745 ,  C07D471/04 ,  A61P33/06 ,  C07D487/04 ,  C07D487/08 ,  C07D519/00

摘要： Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

公开(公告)号：US11753408B2

公开(公告)日：2023-09-12

申请号：US17237351

申请日：2021-04-22

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services ,  Loyola University of Chicago

发明人： Wenwei Huang ,  Hao Li ,  Wei Sun ,  Xiuli Huang ,  Paresma R. Patel ,  Hangmao Sun ,  Wei Zheng ,  Xiao Lu ,  Philip E. Sanderson ,  Myunghoon Kim ,  Meghan J. Orr ,  Gregory J. Tawa ,  Kim C. Williamson

IPC分类号： C07D471/14 ,  A61K31/4375 ,  C07D471/04 ,  A61P33/06 ,  C07D487/04 ,  C07D487/08 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61P33/06 ,  C07D487/04 ,  C07D487/08 ,  C07D519/00

摘要： Disclosed are compounds of formula (I) and formula (II):




wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

公开(公告)号：US10513521B2

公开(公告)日：2019-12-24

申请号：US15326262

申请日：2015-07-14

申请人： The Brigham and Women's Hospital, Inc. ,  The United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health ,  University of Houston System

发明人： Arthur Lee ,  John C. McKew ,  Paresma R. Patel ,  Paul B. Yu ,  Agustin H. Mohedas ,  Philip E. Sanderson ,  Gregory D. Cuny ,  Wei Zheng ,  Xiuli Huang

IPC分类号： C07D487/04 ,  C07D519/00

摘要： The present invention provides bicyclic heteroaryl inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. Exemplary compounds include those of Formula I: These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

公开(公告)号：US11471443B2

公开(公告)日：2022-10-18

申请号：US16861281

申请日：2020-04-29

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  The United States of America, as represented by the Secretary, Department of Health and Human Services ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Hengli Tang ,  Emily M. Lee ,  Wei Zheng ,  Ruili Huang ,  Miao Xu ,  Wenwei Huang ,  Khalida Shamim ,  Guoli Ming ,  Hongjun Song

IPC分类号： A61K31/4162 ,  A61P31/14 ,  A61K31/4184 ,  A61K31/245 ,  A61K31/433 ,  A61K31/4535 ,  A61K31/517 ,  A61K31/4741 ,  A61K31/554 ,  A61K31/422 ,  A61K31/4709 ,  A61K31/336 ,  A61K31/427 ,  A61K31/506 ,  A61K31/519 ,  A61K31/352 ,  A61K31/165

摘要： The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

公开(公告)号：US10555942B2

公开(公告)日：2020-02-11

申请号：US16156124

申请日：2018-10-10

申请人： FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. ,  THE JOHNS HOPKINS UNIVERSITY ,  The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Hengli Tang ,  Emily M. Lee ,  Anil Mathew Tharappel ,  Hongjun Song ,  Guo-Li Ming ,  Wei Zheng ,  Miao Xu ,  Shu Yang ,  Ruili Huang ,  Wenwei Huang ,  Khalida Shamim ,  Hao Li

IPC分类号： A61K31/4745 ,  A61K45/06 ,  A61P31/14

摘要： The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

公开(公告)号：US10301314B2

公开(公告)日：2019-05-28

申请号：US15606740

申请日：2017-05-26

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services ,  University of Kansas ,  Northwestern University

发明人： Kevin Frankowski ,  Samarjit Patnaik ,  Sui Huang ,  Juan Jose Marugan ,  John Norton ,  Frank J. Schoenen ,  Noel Terrence Southall ,  Steven Titus ,  Wei Zheng ,  Chen Wang

IPC分类号： A61K31/519 ,  A61P35/04 ,  C07D487/04 ,  C07F7/18 ,  A61K31/695 ,  A61K45/06

摘要： The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

公开(公告)号：US10239830B2

公开(公告)日：2019-03-26

申请号：US15549743

申请日：2016-02-11

申请人： ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ,  The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Samarjit Patnaik ,  Mercedes Taylor ,  Raul Rolando Calvo ,  Juan Jose Marugan ,  Noel Southall ,  Wei Zheng ,  Marc Ferrer-Alegre ,  Seameen Dehdasthi ,  Patricia Dranchak ,  Fannie Chen ,  Yiannis Ioannou

IPC分类号： C07C311/21 ,  A61K31/4164 ,  A61K31/44 ,  C07D207/335 ,  C07D213/46 ,  C07D233/64 ,  A61K31/165

摘要： Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds is shown in formula 1:

公开(公告)号：US09464035B2

公开(公告)日：2016-10-11

申请号：US14388494

申请日：2013-03-15

申请人： The United States of America, as Represented by the Secretary, Department of Health and Human Services ,  The University of Kansas

发明人： Juan Jose Marugan ,  Wei Zheng ,  Samarjit Patnaik ,  Noel Southall ,  Ellen Sidransky ,  Ehud Goldin ,  Wendy Westbroek ,  Elma Aflaki ,  Steven Andrew Rogers ,  Frank John Schoenen

IPC分类号： C07C235/64 ,  C07C235/60 ,  C07C237/22

CPC分类号： C07C235/64 ,  C07B2200/07 ,  C07C235/60 ,  C07C237/22

摘要： Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.